Aducanumab FDA Approval for Alzheimer's Disease: The Importance of G…

Anton Porsteinsson

Differentiating Early Signs of Alzheimer Disease From Normal Signs o…

ACHL

J. Galvin

Cognitive Disorders

ZINCARE

M. Mataa

Neuromodulators: Making the Right Choice for Your Patient

Douglas Drossman

Approach to Cognitive Impairment in Adults

ZINCARE

M. Mataa

Gut Microbiome and the Brain

BRAIN PONDERINGS podcast with Mark Mattson

J. Cryan

2022 Updates on the Management of Lupus Nephritis

West Virginia State Rheumatology Society

M. Petri

Goals of Diagnosis and Unmet Needs of Inflammatory Bowel Disease in …

David T. Rubin

Early Diagnosis of Alzheimer’s Disease

Sharon Cohen

New & Emerging Treatments in Alzheimer's Disease

University of Miami

E. Crocco

AAIC 2024 Insights: Effects of Gut Microbiota Dysbiosis on Cognitive…

AAIC 2024 Insights Hub

Y. (Laura) Zhang

Updates in Dementia

2023 Conference Coverage

P. Tipton

AAIC 2024 Insights: Potential of Targeting the Alpha-1 Adrenergic Re…

AAIC 2024 Insights Hub

S. G. Pattanashetty

Microbiome Screening in 2024: Ready For Prime Time?

Stanford Medicine

S. Spencer

Alzheimer's: Clinical Pearls

Lawrence Robbins

AAIC 2024 Insights: Developing an AI Algorithm to Detect Predictors …

AAIC 2024 Insights Hub

J. Butler

The Illusion of Progress: Lecanemab in Alzheimer's Disease

Alberto Espay

AAIC 2024 Insights: qEEG as Biomarker for Alzheimer's Disease - Inve…

AAIC 2024 Insights Hub

C. Simfukwe

A New Era for Brain Health in Primary Care: New Drugs and Diagnostics

University of Kansas Medical Center

J. M. Burns

AAIC 2024 Insights: Plasma Aβ42/Aβ40 and Phospho-Tau217 Concentratio…

AAIC 2024 Insights Hub

R. Rissman